BofA analyst Allen Lutz lowered the firm’s price target on Hims & Hers to $21 from $23 and keeps a Neutral rating on the shares. The firm, which estimates GLP-1 EBITDA contributions could decrease 50% this year, sees downside revision risk to 2026 consensus EBITDA estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Mixed options sentiment in Hims and Hers Health with shares down 4.55%
- FDA to ease restrictions on peptides, NY Times reports
- Novo Nordisk launches multi-month subscription program for Wegovy
- Option traders moderately bearish in Hims and Hers Health with shares down 3.43%
- Hims & Hers price target lowered to $23 from $25 at TD Cowen